Back to today’s briefing

Story perspectives

New Trial Offers Hope for Advanced Prostate Cancer Patients

4/17/2025

49 3

Summary

Story summary

The phase 2 SECuRE trial has launched, introducing 67Cu-SAR-bisPSMA to patients battling metastatic castration-resistant prostate cancer (mCRPC). This exciting development comes on the heels of the FDA's approval of lutetium Lu 177 for chemotherapy-naive mCRPC patients, promising a brighter future by enhancing treatment options and postponing the need for chemotherapy.

1 of 1

Story summary

The phase 2 SECuRE trial has launched, introducing 67Cu-SAR-bisPSMA to patients battling metastatic castration-resistant prostate cancer (mCRPC). This exciting development comes on the heels of the FDA's approval of lutetium Lu 177 for chemotherapy-naive mCRPC patients, promising a brighter future by enhancing treatment options and postponing the need for chemotherapy.